文献速递妇科产科

中度(高风险)至重度铂类过敏反应患者门诊脱敏治疗

Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
PubMed 文献 · Gynecol Oncol · 2018-11-29

回顾性分析2011至2017年48例妇科恶性肿瘤患者因中度(高风险)至重度铂类过敏反应接受门诊脱敏方案,共尝试295个脱敏周期,成功完成率96.6%,仅8.3%患者出现重度突破反应,结论认为门诊脱敏安全有效。

要点

  • 门诊铂类脱敏方案在妇科恶性肿瘤患者中成功完成率达96.6%。
  • 约65%患者出现突破反应,但其中超过58%仅发生于首次脱敏周期。
  • 仅8.3%患者出现重度突破反应,均初始接受缩短脱敏方案。

核心结论

  • 门诊铂类脱敏方案对妇科恶性肿瘤患者安全有效。
  • 对于拥有处理铂类过敏反应经验的多学科团队的机构,该方案可能是一种可行的选择。

研究设计与样本

  • 回顾性报告,纳入2011至2017年因中度(高风险)至重度铂类过敏反应接受门诊脱敏方案的妇科恶性肿瘤患者。
  • 共识别48例符合纳入标准的患者,收集人口学特征、化疗史及脱敏方案结局。
  • 鉴于研究的探索性性质,采用描述性统计。

主要发现

  • 多数患者为卵巢癌(56.3%),初次铂类过敏反应时正在接受卡铂治疗者占75.0%。
  • 患者初次过敏反应前平均接受10.3剂铂类。
  • 中度(高风险)过敏反应最常见体征为一过性高血压,重度过敏反应最常见体征为持续性心动过速。
  • 共尝试295个脱敏周期,成功完成率96.6%,患者平均接受5.1个脱敏周期。
  • 约65%患者出现突破反应,其中超过58%仅发生于首次脱敏周期;仅8.3%患者出现重度突破反应。

关键数值与推荐

  • 全部4例重度突破反应患者初始均接受缩短脱敏方案,其中2例经延长方案成功完成脱敏。

临床怎么用

  • 对于拥有处理铂类过敏反应经验的多学科团队的机构,门诊铂类脱敏方案可能是一种可行的选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Platinum hypersensitivity reactions (HSR) affect approximately 5% of the general oncologic population. Here we report the efficacy and safety of outpatient platinum desensitization protocol (PD) in gynecologic oncology patients with moderate (high-risk) to severe platinum HSR. METHODS: This is a retrospective report of patients with gynecologic malignancies undergoing an outpatient PD for moderate (high-risk) to severe platinum HSR from 2011 to 2017. Patient demographics, chemotherapy histories, and PD outcomes were collected. Descriptive statistics were performed given the exploratory nature of the study. RESULTS: Forty-eight patients meeting inclusion criteria were identified. Most patients were being treated for ovarian cancer (56.3%) and were receiving carboplatin during their initial platinum HSR (75.0%). Patients received a mean of 10.3 platinum doses prior to their initial HSR. Transient hypertension was the most common sign of moderate (high-risk) HSR while persistent tachycardia was the most common sign of severe HSR. A total of 295 PD cycles were attempted with a successful completion rate of 96.6%. The mean number of PD cycles received by patients was 5.1. Almost 65% of patients experienced breakthrough reactions but over 58% of these breakthrough reactions were isolated to the first PD cycle. Only 8.3% of patients had severe breakthrough reactions, all of whom initially underwent shortened desensitization. Of these 4 patients, 2 successfully underwent desensitization with a prolonged protocol. CONCLUSION: Outpatient PD is safe and effective in patients with gynecologic malignancies. This may present a feasible option for institutions with multi-disciplinary teams experienced with the management of platinum HSR.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vetter MH, Khan A, Backes FJ, et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2018. PMID: 30503265. doi:10.1016/j.ygyno.2018.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。